At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed advanced, locally advanced, or small volume metastatic pancreatic cancer not amenable to curative surgical resection, or patient unfit or declines surgery
- ✓Age >18 years
- ✓Measurable disease by RECIST criteria
- ✓ECOG performance status 0, 1, or 2
- ✕Porphyria
- ✕Pregnant or breast-feeding
- ✕Locally advanced disease involving >50% circumference of duodenum or major artery within treatment area
- ✕ECOG performance status 3 or 4
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of EUS-Guided Verteporfin PDT in Solid Pancreatic Tumors (VERTPAC-02)
In Brief
A Phase 2 clinical trial evaluating Endoscopic Ultrasound, Fluorescence Imaging, and 4 other interventions for Advanced Pancreatic Carcinoma and 7 related conditions. Completed, enrolled 13 participants across 1 site.
Detailed Summary
This phase II trial studies how well ultrasound-guided verteporfin photodynamic therapy works for the treatment of patients with solid pancreatic tumors that cannot be removed by surgery (unresectable) or pancreatic cancer that has spread to other places in the body (advanced). Photodynamic therapy is a type of laser device that is guided by ultrasound imaging and used in combination with the drug verteporfin that may be less invasive and as effective as current treatment methods for patients with pancreatic cancer.
Study Details
Timeline
Interventions
Undergo EUS-guided PDT
Undergo fluorescence imaging
Undergo EUS-guided PDT
Ancillary studies
Ancillary studies
Given IV